Skip to main content

Advertisement

SpringerLink
Log in

The biology and management of uveal melanoma

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Uveal melanoma is the most common primary intraocular malignancy in adults. Overall mortality rate remains high because of the frequent development of metastatic disease, especially hepatic metastasis. While traditional systemic chemotherapies provide only marginal benefit to patients, local treatments for hepatic metastases, such as immunoembolization, have improved patient prognoses. Progress has also been made in identifying potential targets in the pathways involved in apoptosis, proliferation, invasion, metastasis, and angiogenesis of uveal melanoma. Among these pathways, the c-Kit, c-Met, and IGF-1R signal pathways and the PTEN-related P13K-Akt pathway are the most important targets. Clinical trials using blockades of these pathways in conjunction with strategies to facilitate apoptosis is a direction for future clinical trials. Application of these approaches in the adjuvant setting after primary therapy for high-risk uveal melanoma patients is also a future consideration to improve the clinical outcome of this disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Singh AD, Bergman L, Seregard S: Uveal melanoma: epidemiologic aspects. Ophthalmol Clin North Am 2005, 18:75–84, viii.

    Article  PubMed  Google Scholar 

  2. Shields CL, Shields JA: Recent developments in the management of choroidal melanoma. Curr Opin Ophthalmol 2004, 15:244–251.

    Article  PubMed  Google Scholar 

  3. Gragoudas ES, Egan KM, Seddon JM, et al.: Survival of patients with metastases from uveal melanoma. Ophthalmology 1991, 98:383–389; discussion 390.

    PubMed  CAS  Google Scholar 

  4. Kujala E, Makitie T, Kivela T: Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 2003, 44:4651–4659.

    Article  PubMed  Google Scholar 

  5. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol 2001, 119:670–676.

    Google Scholar 

  6. Liu W, Kelly JW, Trivett M, et al.: Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. J Invest Dermatol 2007, 127:900–905.

    Article  PubMed  CAS  Google Scholar 

  7. Davies H, Bignell GR, Cox C, et al.: Mutations of the BRAF gene in human cancer. Nature 2002, 417:949–954.

    Article  PubMed  CAS  Google Scholar 

  8. Cruz F III, Rubin BP, Wilson D, et al.: Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res 2003, 63:5761–5766.

    PubMed  CAS  Google Scholar 

  9. de Snoo FA, Bergman W, Gruis NA: Familial melanoma: a complex disorder leading to controversy on DNA testing. Fam Cancer 2003, 2:109–116.

    Article  PubMed  Google Scholar 

  10. Ohta M, Nagai H, Shimizu M, et al.: Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma. Cancer Res 1994, 54:5269–5272.

    PubMed  CAS  Google Scholar 

  11. Singh AD, Shields CL, Shields JA: Prognostic factors in uveal melanoma. Melanoma Res 2001, 11:255–263.

    Article  PubMed  CAS  Google Scholar 

  12. Becher R, Korn WM, Prescher G: Use of fluorescence in situ hybridization and comparative genomic hybridization in the cytogenetic analysis of testicular germ cell tumors and uveal melanomas. Cancer Genet Cytogenet 1997, 93:22–28.

    Article  PubMed  CAS  Google Scholar 

  13. Tschentscher F, Prescher G, Horsman DE, et al.: Partial deletions of the long and short arm of chromosome 3 point to two tumor suppressor genes in uveal melanoma. Cancer Res 2001, 61:3439–3442.

    PubMed  CAS  Google Scholar 

  14. Sisley K, Parsons MA, Garnham J, et al.: Association of specific chromosome alterations with tumour phenotype in posterior uveal melanoma. Br J Cancer 2000, 82:330–338.

    Article  PubMed  CAS  Google Scholar 

  15. Chana JS, Wilson GD, Cree IA, et al.: C-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma. Br J Ophthalmol 1999, 83:110–114.

    Article  PubMed  CAS  Google Scholar 

  16. Parrella P, Sidransky D, Merbs SL: Allelotype of posterior uveal melanoma: implications for a bifurcated tumor progression pathway. Cancer Res 1999, 59:3032–3037.

    PubMed  CAS  Google Scholar 

  17. Hoglund M, Gisselsson D, Hansen GB, et al.: Dissecting karyotypic patterns in malignant melanomas: temporal clustering of losses and gains in melanoma karyotypic evolution. Int J Cancer 2004, 108:57–65.

    Article  PubMed  CAS  Google Scholar 

  18. Griffin CA, Long PP, Schachat AP: Trisomy 6p in an ocular melanoma. Cancer Genet Cytogenet 1988, 32:129–132.

    Article  PubMed  CAS  Google Scholar 

  19. Prescher G, Bornfeld N, Hirche H, et al.: Prognostic implications of monosomy 3 in uveal melanoma. Lancet 1996, 347:1222–1225.

    Article  PubMed  CAS  Google Scholar 

  20. Onken MD, Worley LA, Ehlers JP, Harbour JW: Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 2004, 64:7205–7209.

    Article  PubMed  CAS  Google Scholar 

  21. Onken MD, Ehlers JP, Worley LA, et al.: Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas. Cancer Res 2006, 66:4602–4609.

    Article  PubMed  CAS  Google Scholar 

  22. Zuidervaart W, Pavey S, van Nieuwpoort FA, et al.: Expression of Wnt5a and its downstream effector beta-catenin in uveal melanoma. Melanoma Res 2007, 17:380–386.

    PubMed  CAS  Google Scholar 

  23. Bedikian AY: Metastatic uveal melanoma therapy: current options. Int Ophthalmol Clin 2006, 46:151–166.

    Article  PubMed  Google Scholar 

  24. Bedikian AY, Legha SS, Mavligit G, et al.: Treatment of uveal melanoma metastatic to the liver: a review of the M.D. Anderson Cancer Center experience and prognostic factors. Cancer 1995, 76:1665–1670.

    Article  PubMed  CAS  Google Scholar 

  25. Aoyama T, Mastrangelo MJ, Berd D, et al.: Protracted survival after resection of metastatic uveal melanoma. Cancer 2000, 89:1561–1568.

    Article  PubMed  CAS  Google Scholar 

  26. Leyvraz S, Spataro V, Bauer J, et al.: Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol 1997, 15:2589–2595.

    PubMed  CAS  Google Scholar 

  27. Cantore M, Fiorentini G, Aitini E, et al.: Intra-arterial hepatic carboplatin-based chemotherapy for ocular melanoma metastatic to the liver. Report of a phase II study. Tumori 1994, 80:37–39.

    PubMed  CAS  Google Scholar 

  28. Alexander HR, Libutti SK, Bartlett DL, et al.: A phase I–II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res 2000, 6:3062–3070.

    PubMed  CAS  Google Scholar 

  29. Mavligit GM, Charnsangavej C, Carrasco CH, et al.: Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA 1988, 260:974–976.

    Article  PubMed  CAS  Google Scholar 

  30. Patel K, Sullivan K, Berd D, et al.: Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study. Melanoma Res 2005, 15:297–304.

    Article  PubMed  Google Scholar 

  31. Sato T, Eschelman DJ, Gonsalves CF, et al.: Immunoembolization of malignant liver tumors using granulocyte-macrophage colony-stimulating factor (GM-CSF, Ssargramostim): a novel treatment for uveal melanoma patients with hepatic metastases. J Clin Oncol 2008 [In press].

  32. Gonsalves CF, Sullivan K, Eschelman DJ, et al.: Treatment of uveal melanoma liver metastases using Y-90 SIR-Spheres: imaging and clinical response [abstract 128]. J Vasc Interv Radiol 2008, 19:S50.

    Article  Google Scholar 

  33. Natali PG, Nicotra MR, Winkler AB, et al.: Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor. Int J Cancer 1992, 52:197–201.

    Article  PubMed  CAS  Google Scholar 

  34. Bar-Eli M: Molecular mechanisms of melanoma metastasis. J Cell Physiol 1997, 173:275–278.

    Article  PubMed  CAS  Google Scholar 

  35. Pache M, Glatz K, Bosch D, et al.: Sequence analysis and high-throughput immunohistochemical profiling of KIT (CD 117) expression in uveal melanoma using tissue microarrays. Virchows Arch 2003, 443:741–744.

    Article  PubMed  CAS  Google Scholar 

  36. Mouriaux F, Kherrouche Z, Maurage CA, et al.: Expression of the c-kit receptor in choroidal melanomas. Melanoma Res 2003, 13:161–166.

    Article  PubMed  CAS  Google Scholar 

  37. Mouriaux F, Chahud F, Maurage CA, et al.: Implication of stem cell factor in the proliferation of choroidal melanocytes. Exp Eye Res 2001, 73:151–157.

    Article  PubMed  CAS  Google Scholar 

  38. Lefevre G, Glotin AL, Calipel A, et al.: Roles of stem cell factor/c-Kit and effects of Glivec/STI571 in human uveal melanoma cell tumorigenesis. J Biol Chem 2004, 279:31769–31779.

    Article  PubMed  CAS  Google Scholar 

  39. Chan KR, Gundala S, Laudadio M, et al.: A pilot study using sunitinib malate as therapy in patients with stage IV uveal melanoma [abstract 9047]. J Clin Oncol 2008, 26(15S):494s.

    Google Scholar 

  40. Mallikarjuna K, Pushparaj V, Biswas J, et al.: Expression of epidermal growth factor receptor, ezrin, hepatocyte growth factor, and c-Met in uveal melanoma: an immunohistochemical study. Curr Eye Res 2007, 32:281–290.

    Article  PubMed  CAS  Google Scholar 

  41. Di Cesare S, Marshall JC, Logan P, et al.: Expression and migratory analysis of 5 human uveal melanoma cell lines for CXCL12, CXCL8, CXCL1, and HGF. J Carcinog 2007, 6:2.

    PubMed  Google Scholar 

  42. Peruzzi B, Bottaro DP: Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 2006, 12:3657–3660.

    Article  PubMed  CAS  Google Scholar 

  43. Economou MA, All-Ericsson C, Bykov V, et al.: Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications. Invest Ophthalmol Vis Sci 2005, 46:4372–4375.

    Article  PubMed  Google Scholar 

  44. All-Ericsson C, Girnita L, Seregard S, et al.: Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target. Invest Ophthalmol Vis Sci 2002, 43:1–8.

    PubMed  Google Scholar 

  45. Adhami VM, Afaq F, Mukhtar H: Insulin-like growth factor-I axis as a pathway for cancer chemoprevention. Clin Cancer Res 2006, 12:5611–5614.

    Article  PubMed  CAS  Google Scholar 

  46. Girnita A, All-Ericsson C, Economou MA, et al.: The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells. Clin Cancer Res 2006, 12:1383–1391.

    Article  PubMed  CAS  Google Scholar 

  47. Abdel-Rahman MH, Yang Y, Zhou XP, et al.: High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma. J Clin Oncol 2006, 24:288–295.

    Article  PubMed  CAS  Google Scholar 

  48. Saraiva VS, Caissie AL, Segal L, et al.: Immunohistochemical expression of phospho-Akt in uveal melanoma. Melanoma Res 2005, 15:245–250.

    Article  PubMed  CAS  Google Scholar 

  49. Granville CA, Memmott RM, Gills JJ, et al.: Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin Cancer Res 2006, 12(3 Pt 1):679–689.

    Article  PubMed  CAS  Google Scholar 

  50. Margolin K, Longmate J, Baratta T, et al.: CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer 2005, 104:1045–1048.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Thomas Jefferson University, 1015 Walnut Street, Suite 1024, Philadelphia, PA, 19107, USA

    Takami Sato

Authors
  1. Takami Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fei Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Akira Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takami Sato.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sato, T., Han, F. & Yamamoto, A. The biology and management of uveal melanoma. Curr Oncol Rep 10, 431–438 (2008). https://doi.org/10.1007/s11912-008-0066-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-008-0066-z

Keywords

Search

Navigation